Drug Manufacturers, Technology

Container Closure Integrity of Rubber-stoppered, Glass, and Plastic Vials

An increasing number of pharmaceuticals including vaccines, stem cells, and proteins require cold storage to maintain efficacy prior to use.

However, the ability to maintain container closure integrity (CCI) during cold storage is still not completely understood. Concerns about CCI failure have been raised for the storage and shipment of pharmaceutical products in rubber-stoppered vials under cold conditions (such as -80°C or dry ice).

Commonly used butyl stoppers are believed to lose their elastic properties below their glass transition temperature (Tg) posing a risk to sealability. The temporary loss of CCI under cold conditions can allow cold, dense gas from the surrounding low-temperature storage environment to leak into the stored vial.

Ingress of the gas can contribute to loss of efficacy of the stored drug product due to interaction with the gas as well as overpressurisation of the vial. Overpressurisation occurs when cold, dense gas becomes trapped within the vial as the rubber stopper warms to a temperature above its Tg after it is removed from the cold storage conditions.

Download this free whitepaper to learn more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.